# Overview of Antiretroviral Therapy 

Kathryn Snyder and Quinton Taylor

---

<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 18%" />
<col style="width: 25%" />
<col style="width: 41%" />
</colgroup>
<tbody>
<tr class="odd">
<td colspan="2"><strong>Fixed Dose Combination regimens</strong></td>
<td><strong>Renal Dosing</strong></td>
<td><strong>Specific Considerations</strong></td>
</tr>
<tr class="even">
<td>Biktarvy®</td>
<td>Bictegravir/ Emtricitabine/ Tenofovir (Alafenamide)</td>
<td>Discontinue if CrCl &lt; 30; ok w/HD</td>
<td><p>↑ Metformin levels</p>
<p>Contraindicated with: rifampin, dofetilide, rifabutin</p>
<p>Avoid close admin. with: laxatives, sucralfate, polyvalent cations
(iron, calcium, etc.)</p></td>
</tr>
<tr class="odd">
<td>Dovato®</td>
<td><p>Doltegravir/</p>
<p>Lamivudine</p></td>
<td><p>CrCl 30-50: monitor for hematologic toxicities with
lamivudine</p>
<p>CrCl&lt;30: do not use combo pill; dose-adjust individual
components</p></td>
<td><p>↑ Metformin levels</p>
<p>Dose adjustment needed with rifampin use</p>
<p>Contraindicated w/dofetilide and multiple antiepileptic drugs</p>
<p>Avoid close admin. with polyvalent cations (iron, calcium, etc.)</p>
<p>Test all patients for HBV prior to initiation</p></td>
</tr>
<tr class="even">
<td>Symtuza®</td>
<td><p>Tenofavir alafenamide/</p>
<p>Emtricitabin/</p>
<p>Darunavir/</p>
<p>Cobistat</p></td>
<td>Discontinue if CrCl&lt;30; ok w/HD but dose after HD on dialysis
days</td>
<td><p>Contraindicated w/rifampin, rifabutin, simvastatin, multiple
antiepileptic drugs</p>
<p>Note that cobistat can increase serum creatinine without affecting
glomerular filtration so cautiously interpret serum creatinine
levels</p></td>
</tr>
<tr class="odd">
<td>Triumeq®</td>
<td>Abacavir/ Dolutegravir/ Lamivudine</td>
<td><p>CrCL 30-50: monitor for hematologic toxicities with
lamivudine</p>
<p>CrCl&lt; 30; do not use combo pill; dose-adjust individual
components</p></td>
<td><p>↑ Metformin levels</p>
<p>Dose adjustment needed with rifampin use</p>
<p>Contraindicated w/dofetilide and multiple antiepileptic drugs</p>
<p>Avoid close admin. with polyvalent cations (iron, calcium, etc.)</p>
<p>Test all patients for HBV prior to initiation</p></td>
</tr>
<tr class="even">
<td>Genvoya®</td>
<td><p>Elvitegravir/ Cobicistat/ Emtricitabin/</p>
<p>Tenofovir (Alafenamide)</p></td>
<td>Discontinue if CrCl &lt; 30; ok w/HD</td>
<td>Many drug-drug interactions due to CYP 3A4 inhibition with
cobicistat</td>
</tr>
</tbody>
</table>

<table>
<colgroup>
<col style="width: 18%" />
<col style="width: 20%" />
<col style="width: 26%" />
<col style="width: 17%" />
<col style="width: 16%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Nucleoside RTI</strong></td>
<td><strong>Dose adj</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Abacavir (ABC)</td>
<td>Hepatic dysfunction</td>
<td><p>↑ LDL/TG</p>
<p>↑ risk MI</p></td>
<td>Tenofovir</td>
<td>Requires testing for HLA B5701</td>
</tr>
<tr class="odd">
<td><p>Emtricitabine</p>
<p>(FTC)</p></td>
<td>Renal</td>
<td>Rash, insomnia, rhabdomyolysis, hyperpigmentation in
palms/soles</td>
<td>Lamivudine</td>
<td>Active against HBV</td>
</tr>
<tr class="even">
<td><p>Lamivudine</p>
<p>(3TC)</p></td>
<td>Renal</td>
<td>Nausea, HA, peripheral neuropathy, neutropenia, rash</td>
<td>Emtricitabine</td>
<td>Active against HBV</td>
</tr>
<tr class="odd">
<td>Tenofovir Alafenamide (TAF)</td>
<td>Discontinue if CrCl &lt; 15</td>
<td>↑ lipids</td>
<td>AED’s may ↑ levels</td>
<td>Tx of choice for HBV</td>
</tr>
<tr class="even">
<td>Tenofovir Disoproxil (TDF)</td>
<td>Renal</td>
<td>N/V, ↑ LFTs, asymptomatic ↑CK, renal dysfunction, bone mineral
density loss</td>
<td><blockquote>
<p>--</p>
</blockquote></td>
<td>Active against HBV</td>
</tr>
</tbody>
</table>

NRTI Additional Information

- Tenofovir alone is indicated for HBV, in which case you should be
    mindful of renal clearance when dosing. In HIV, it is only used in
    combination with emtricitabine and third agent. Contraindicated if
    CrCl\<30

- Class-wide side effect: Lactic acidosis, steatosis and lipoatrophy
    (though very rare with contemporary NRTIs)

- Resistance: M184V confers high resistance to emtricitabine and
    lamivudine, mid-level resistance to abacavir, hypersusceptibility to
    tenofovir

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 14%" />
<col style="width: 20%" />
<col style="width: 16%" />
<col style="width: 29%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Integrase Inhibitor</strong></td>
<td><strong>Dose Adj.</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Raltegravir (RAL)</td>
<td><blockquote>
<p>--</p>
</blockquote></td>
<td><blockquote>
<p>--</p>
</blockquote></td>
<td>Rifampin, AED’s</td>
<td><blockquote>
<p>--</p>
</blockquote></td>
</tr>
<tr class="odd">
<td>Dolutegravir (DTG)</td>
<td>*see special points*</td>
<td><p>Hyperglycemia</p>
<p>Weight gain</p></td>
<td><p>Rifampin, Efavirenz</p>
<p>↑Metformin</p></td>
<td><p>Avoid close admin with laxatives, sucralfate, iron, calcium</p>
<p>May ↑Cr, without effect on renal function</p></td>
</tr>
</tbody>
</table>

<table style="width:100%;">
<colgroup>
<col style="width: 15%" />
<col style="width: 13%" />
<col style="width: 24%" />
<col style="width: 23%" />
<col style="width: 22%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>NNRTIs</strong></td>
<td><strong>Hepatic Adj</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Efavirenz</td>
<td>Stop if Child Pugh B/C</td>
<td><p>Psychosis, vivid dreams, SI, mania, seizures;</p>
<p>↑ Lipids &amp; glucose</p></td>
<td>Azoles, antifungals, clopidogrel, some statins, clarithromycin,
Buprenorphine</td>
<td>Give before meals; discontinue if rash develops</td>
</tr>
<tr class="odd">
<td>Etravirine (ETR)</td>
<td></td>
<td><p>Hypersensitivity</p>
<p>↑ Lipids &amp; glucose</p></td>
<td>Clopidogrel, clarithromycin</td>
<td></td>
</tr>
<tr class="even">
<td>Nevirapine (NVP)</td>
<td>Stop if Child Pugh B/C</td>
<td>Steven Johnson Syndrome</td>
<td>Azoles, OCP’s, statins, clarithromycin</td>
<td><p>Don’t start if CD4 &gt;250 in women, CD4 &gt;400 in men;</p>
<p>Don’t admin with antacids</p></td>
</tr>
<tr class="odd">
<td>Rilpivirine (RPV)</td>
<td></td>
<td>None</td>
<td>AED’s, PPI’s, dexamethasone</td>
<td><p>Must be taken with full meal; Don’t use if HIV RNA &gt;100k + CD4
&lt; 200;</p>
<p>Don’t admin with antacids</p></td>
</tr>
</tbody>
</table>

NNRTI Additional Information

- Class-wide side effect: hepatitis, rashes

- Resistance: K103N resistance to efavirenz and nevirapine

<table>
<colgroup>
<col style="width: 16%" />
<col style="width: 14%" />
<col style="width: 30%" />
<col style="width: 24%" />
<col style="width: 14%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Protease inhibitors</strong></td>
<td><strong>Hepatic Dose adj</strong></td>
<td><strong>Specific Side Effects</strong></td>
<td><strong>Major DDI</strong></td>
<td><strong>Special Points</strong></td>
</tr>
<tr class="even">
<td>Atazanavir (ATV)</td>
<td>Based on Childs Pugh</td>
<td>Jaundice, Kidney stones, AV block, Pancreatitis, Rhabdomyolysis</td>
<td><p>CYP3A4 Inhibitors</p>
<p>PPI and H2 blockers</p></td>
<td>Admin with meals</td>
</tr>
<tr class="odd">
<td>Darunavir (DRV)</td>
<td></td>
<td><p>Rashes</p>
<p>Pancreatitis</p></td>
<td><p>CYP3A4 Inhibitors</p>
<p>Azoles can be used cautiously with drug level monitoring</p></td>
<td>Must stop if rash</td>
</tr>
<tr class="even">
<td>Lopinavir (LPV)</td>
<td></td>
<td><p>AV block, QT changes</p>
<p>Pancreatitis</p>
<p>Hepatitis</p></td>
<td>CYP3A4 Inhibitors</td>
<td>Admin with meals</td>
</tr>
</tbody>
</table>

Protease Inhibitor Additional Information

- All protease inhibitors must be boosted:

<!-- -->

- Ritonavir: can cause MSK pain, rhabdomyolysis, although not expected
    at usual doses

- Cobicistat: may increase Cr without effect on renal function

<!-- -->

- Class-wide side effects: hepatitis, hypersensitivity reactions,
    increased cholesterol/TG, hyperglycemia, GI upset, lipodystrophy
